Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bone marrow cancer, such as myelofibrosis, polycythemia vera, or essential thrombocytosis.
- You should have at least 2 moderate-to-severe symptoms (like fatigue, night sweats, or belly pain) or a high total symptom score.
- You must have tried a JAK2 inhibitor (like ruxolitinib) for at least 12 weeks and it didn't work, or you developed a new enlarged spleen during treatment.
- You need to be 18 or older and have a good performance status (able to do daily activities with some help if needed).
- You cannot have other active cancers (except some well-controlled ones), uncontrolled infections, heart problems, or a history of bleeding stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.